JP2021038198A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021038198A5 JP2021038198A5 JP2020129462A JP2020129462A JP2021038198A5 JP 2021038198 A5 JP2021038198 A5 JP 2021038198A5 JP 2020129462 A JP2020129462 A JP 2020129462A JP 2020129462 A JP2020129462 A JP 2020129462A JP 2021038198 A5 JP2021038198 A5 JP 2021038198A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- subject
- clovalimab
- medicament according
- kurobarimabu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022036164A JP7748311B2 (ja) | 2019-07-31 | 2022-03-09 | 抗ｃ５抗体クロバリマブの使用によるｃ５関連疾患の治療または予防のための薬用量および投与レジメン |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19189442 | 2019-07-31 | ||
| EP19189442 | 2019-07-31 | ||
| EP20174790 | 2020-05-14 | ||
| EP20174790 | 2020-05-14 | ||
| EP20179591 | 2020-06-11 | ||
| EP20179591 | 2020-06-11 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022036164A Division JP7748311B2 (ja) | 2019-07-31 | 2022-03-09 | 抗ｃ５抗体クロバリマブの使用によるｃ５関連疾患の治療または予防のための薬用量および投与レジメン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021038198A JP2021038198A (ja) | 2021-03-11 |
| JP2021038198A5 true JP2021038198A5 (https=) | 2021-08-19 |
| JP7437261B2 JP7437261B2 (ja) | 2024-02-22 |
Family
ID=71846415
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020129462A Active JP7437261B2 (ja) | 2019-07-31 | 2020-07-30 | 抗ｃ５抗体クロバリマブの使用によるｃ５関連疾患の治療または予防のための薬用量および投与レジメン |
| JP2022036164A Active JP7748311B2 (ja) | 2019-07-31 | 2022-03-09 | 抗ｃ５抗体クロバリマブの使用によるｃ５関連疾患の治療または予防のための薬用量および投与レジメン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022036164A Active JP7748311B2 (ja) | 2019-07-31 | 2022-03-09 | 抗ｃ５抗体クロバリマブの使用によるｃ５関連疾患の治療または予防のための薬用量および投与レジメン |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220275070A1 (https=) |
| EP (1) | EP4003409A1 (https=) |
| JP (2) | JP7437261B2 (https=) |
| KR (2) | KR20210016333A (https=) |
| CN (2) | CN115068604A (https=) |
| AU (1) | AU2020322165A1 (https=) |
| CA (1) | CA3144923A1 (https=) |
| CR (1) | CR20220041A (https=) |
| IL (1) | IL288600B1 (https=) |
| MX (1) | MX2022001154A (https=) |
| TW (1) | TWI886140B (https=) |
| WO (1) | WO2021019036A1 (https=) |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| AU2001296594A1 (en) | 2000-10-10 | 2002-04-22 | Tanox, Inc. | Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection |
| BRPI0211953B8 (pt) | 2001-08-17 | 2021-05-25 | Genentech Inc | anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro |
| ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP3263596A1 (en) | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| US20070116710A1 (en) | 2004-02-03 | 2007-05-24 | Leonard Bell | Methods of treating hemolytic anemia |
| US20050169921A1 (en) | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| KR100891620B1 (ko) | 2004-04-13 | 2009-04-02 | 에프. 호프만-라 로슈 아게 | 항-ｐ-셀렉틴 항체 |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| PL3167888T3 (pl) | 2006-03-15 | 2024-08-26 | Alexion Pharmaceuticals, Inc. | Leczenie pacjentów z napadową nocną hemoglobinurią za pomocą inhibitora dopełniacza |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| LT2894165T (lt) | 2008-11-10 | 2023-03-10 | Alexion Pharmaceuticals, Inc. | Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui |
| CN107207607B (zh) * | 2014-12-19 | 2021-05-04 | 中外制药株式会社 | 抗-c5抗体及使用方法 |
| IL259256B2 (en) | 2015-12-18 | 2023-02-01 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
| EP3402816A1 (en) | 2016-01-11 | 2018-11-21 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment |
| EP3408291A1 (en) | 2016-01-25 | 2018-12-05 | Shire Human Genetic Therapies, Inc. | Anti-c5 antibodies with enhanced ph switch |
| EP3554543A4 (en) * | 2016-12-16 | 2020-09-02 | Samsung Bioepis Co., Ltd. | STABLE Aqueous ANTI-C5 ANTIBODY COMPOSITION |
| IL307593A (en) | 2017-01-31 | 2023-12-01 | Chugai Pharmaceutical Co Ltd | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease |
| CA3080187A1 (en) * | 2017-10-26 | 2019-05-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) |
-
2020
- 2020-07-30 CN CN202210578978.0A patent/CN115068604A/zh active Pending
- 2020-07-30 MX MX2022001154A patent/MX2022001154A/es unknown
- 2020-07-30 TW TW109125890A patent/TWI886140B/zh active
- 2020-07-30 KR KR1020207030736A patent/KR20210016333A/ko not_active Ceased
- 2020-07-30 CN CN202080054557.7A patent/CN114929273A/zh active Pending
- 2020-07-30 IL IL288600A patent/IL288600B1/en unknown
- 2020-07-30 US US17/630,046 patent/US20220275070A1/en active Pending
- 2020-07-30 KR KR1020247006223A patent/KR20240033090A/ko active Pending
- 2020-07-30 JP JP2020129462A patent/JP7437261B2/ja active Active
- 2020-07-30 WO PCT/EP2020/071555 patent/WO2021019036A1/en not_active Ceased
- 2020-07-30 EP EP20747415.6A patent/EP4003409A1/en active Pending
- 2020-07-30 CR CR20220041A patent/CR20220041A/es unknown
- 2020-07-30 CA CA3144923A patent/CA3144923A1/en active Pending
- 2020-07-30 AU AU2020322165A patent/AU2020322165A1/en active Pending
-
2022
- 2022-03-09 JP JP2022036164A patent/JP7748311B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008212250B2 (en) | Therapeutic agent for pain disease | |
| US11364277B2 (en) | Treatment of ascites | |
| US10329570B2 (en) | Antagonistic PD-1 aptamer and its applications in cancer therapy related applications | |
| JP2021038198A5 (https=) | ||
| CN117243956A (zh) | 一种用于治疗结核分枝杆菌感染的药物组合物及其应用 | |
| CN108939074A (zh) | 治疗再生障碍性贫血的方法和药物组合物 | |
| JP2021527133A (ja) | 免疫応答の促進 | |
| WO2023272831A1 (zh) | 水苏糖在制备用于治疗去势抵抗性前列腺癌药物中的应用 | |
| CN101068564A (zh) | 含有vegf抑制剂与5fu或其中一种衍生物的抗肿瘤组合物 | |
| US20070141044A1 (en) | Method for treating cancer patients undergoing chemotherapy | |
| RU2024129928A (ru) | Дозировка и схема введения для лечения или предупреждения синдрома гийена-барре с применением антитела к c5 кровалимаба | |
| JPWO2023194273A5 (https=) | ||
| RU2024129212A (ru) | Дозировка и схема введения для лечения или предупреждения синдрома гийена-барре с применением антитела к c5 кровалимаба | |
| CN115554285B (zh) | 3-去甲基秋水仙碱在药物中的应用 | |
| JPWO2023194271A5 (https=) | ||
| CN110833553A (zh) | 吡唑并嘧啶衍生物在治疗Arthus反应的用途 | |
| RU2024107307A (ru) | Способ коррекции тромбоцитопении у детей с приобретенной тромботической тромбоцитопенической пурпурой | |
| Tola | Corticosteroid in Septic Shock: Advantage or Disadvantage? | |
| CN120114599A (zh) | Gpr55抑制剂在制备用于增强肿瘤免疫效果的产品中的应用 | |
| Triner et al. | Hypoglycemic effect of ouabain in dogs | |
| CN118976012A (zh) | 一种gsdmd抑制剂预防化疗时外周神经损伤的用途 | |
| RU2022103727A (ru) | Дозировка и схема введения для лечения или предупреждения связанных с с5 заболеваний посредством применения антитела против с5 кровалимаба | |
| NZ781127B2 (en) | Mirikizumab for use in a method of treating crohn's disease | |
| CN119326894A (zh) | Gsdme抑制剂用于制造预防和治疗化疗时外周神经损伤的药物的用途 | |
| RU2022103731A (ru) | Дозировка и схема введения для лечения или предупреждения связанных с с5 заболеваний посредством применения антитела против с5 кровалимаба |